![Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic Acid (Setipiprant/ACT-129968)](/images/assets/d743d32f-3115-48ff-9697-2f2d56130701/small/14175.jpg)
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.
24 citations
,
August 2017 in “Prostaglandins & Other Lipid Mediators” This review discusses the potential roles of prostaglandin D2 and its receptor CRTH2 in various diseases beyond allergies and asthma and reports no new clinical results.
2 citations
,
April 2012 in “Science-business Exchange” Blocking a protein called prostaglandin D2 might help treat hair loss.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.
1 citations
,
April 2016 in “Journal of Investigative Dermatology” This study identified that blocking the PTGDR2 receptor in human hair follicles in vitro and in mice reversed the hair growth inhibition caused by PGD2, suggesting a potential approach for treating alopecia.